J&J’s nasal spray antidepressant wins U.S. approvalAnesthetics, Approvals, Boxed Warning, Elevated Blood Pressure, FDA, FDA/Regulatory, Major Depressive Disorder (MDD), Nasal Sprays, Potential Blockbusters, Treatment-Resistant DepressionThe U.S. FDA approved Johnson & Johnson’s nasal spray antidepressant Spravato for people resistant to other treatments, but placed restrictions on use of the drug. Read more March 5, 2019/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2019-03-05 20:15:022019-03-06 13:15:40J&J’s nasal spray antidepressant wins U.S. approval
